Timothy J. Eberlein, MD, FACS, a surgical oncologist from St. Louis, MO, was elected Chair of the ACS Board of Regents (BoR) following the conclusion of the ACS Clinical Congress 2022 in San Diego, CA.
Dr. Eberlein is the Spencer T. and Ann W. Olin Distinguished Professor, director of the Alvin J. Siteman Cancer Center, and senior associate dean for cancer programs at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, MO.
In his 1-year term, Dr. Eberlein will work closely with ACS Executive Director and CEO Patricia L. Turner, MD, MBA, FACS, and chair the Regents’ Finance and Executive Committees. The College’s 24-member BoR formulates policy and ultimately is responsible for overseeing the affairs of the ACS.
Dr. Eberlein has been an ACS Fellow since 1988 and a member of the ACS BoR since 2015. He has served as Editor-in-Chief of the Journal of the American College of Surgeons (JACS) since 2004. Under his editorial leadership, the impact factor of JACS—which indicates the influence of a journal by measuring the frequency with which the average article has been cited in a particular year—is at a record high 6.532. JACS now ranks 14th among the 211 journals in the surgery category.
A member of the ACS Academy of Master Surgeon Educators® since 2019, Dr. Eberlein’s service to the ACS has been extensive. He served on the ACS Board of Governors (2004–2010) as a specialty society Governor from the Society of Surgical Oncology, has been a member of the ACS Commission on Cancer since 1995, and was Vice-Chair of the ACS Committee for the Forum on Fundamental Surgical Problems (2000–2004). He also was extensively involved in the ACS Oncology Group (now the Alliance for Clinical Trials in Oncology) and the ACS Surgical Research and Education Committee, for which he served as Chair (2000–2002). Beyond his considerable work with the ACS, Dr. Eberlein has been an active member of several other specialty healthcare organizations.
In 2004, Dr. Eberlein was elected to the National Academy of Medicine and as a Fellow of the American Association for the Advancement of Science in 2018. He also holds multiple honorary fellowships.
Dr. Eberlein’s research interests include tumor immunology and immune therapies using T-cells and T-cell subpopulations, tumor/lymphocyte interactions and their role in tumor rejection, identification of tumor-associated antigens, identification of the co-stimulatory molecules and pathways in human solid tumors, and clinical aspects of therapy for breast cancer. He is author or coauthor of nearly 200 peer-reviewed articles and has been the recipient of numerous awards throughout his career.
